Fosun International Limited's Henlius recently announced the presentation of updated phase 2 results and the design for a phase 3 clinical trial of their anti-HER2 monoclonal antibody, HLX22, targeting first-line HER2-positive gastric cancer. The announcement was made at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The phase 2 study results highlight the efficacy and safety of HLX22 in combination with trastuzumab and chemotherapy, with over two years of follow-up data. The phase 3 trial, HLX22-GC-301, will compare HLX22 with the current standard of care therapy, enrolling approximately 550 patients globally. The trial will evaluate progression-free survival and overall survival as dual primary endpoints. Additionally, HLX22's scope has expanded to include breast cancer, with a phase 2 trial for HER2-low, hormone receptor-positive breast cancer underway in China.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.